The Centers for Medicare & Medicaid Services yesterday released a memo and timeline outlining how it will approach implementing the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which will negotiate prices with drug makers for certain high-cost, sole-source drugs and apply them beginning in 2026. According to the memo, CMS plans to actively engage hospitals and other stakeholders in the policymaking process. 

Related News Articles

Headline
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug…
Headline
The Centers for Medicare & Medicaid Services Sept. 27 announced that average premiums, benefits and plan choices for Medicare Advantage and Part D will…
Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…